Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,293 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiac Ischemia Clear all

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale; Drug · Behavioral
Lead sponsor: Cardiovascular Imaging Technologies; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
Interventions: Orticumab, Placebo; Drug
Lead sponsor: Abcentra; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Torrance, California • Boca Raton, Florida + 4 more

Conditions: Coronary Disease
Interventions: rNAPc2; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Coronary Artery Disease (S-CAD)
Interventions: Not listed
Lead sponsor: Spirocor; Industry
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 25 more

Conditions: Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease (CAD)
Interventions: Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI); Drug · Procedure
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 60
States / cities: Mobile, Alabama • Fremont, California • Long Beach, California + 52 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: CoreAalst BV; Industry
Eligibility: 21 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Decatur, Georgia • Bangor, Maine

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tustin, California

Conditions: Coronary Artery Disease
Interventions: Frequency domain optical coherence tomography; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Coronary CT Angiography (CCTA); Device
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Angina Pectoris
Interventions: Osteopathic manipulation; Procedure
Lead sponsor: University of New England; Other
Eligibility: 18 Years to 81 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Saco, Maine

Conditions: Coronary Artery Disease
Interventions: Bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking, Acute Coronary Syndrome
Interventions: Varenicline 100 mg by mouth twice daily, control; Drug
Lead sponsor: Newark Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury
Interventions: portable MRI scanner; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Interventions: Day Light, Placebo light, ICU Intense Light, ICU Placebo light; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina, STEMI, NSTEMI - Non-ST Segment Elevation MI
Interventions: MBCT intervention for ACS patients; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myocardial Ischemia
Interventions: No intervention; Drug
Lead sponsor: Aiden Abidov; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel, Placebo for Prasugrel, Placebo for Clopidogrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus, Seizures, Anoxic-Ischemic Encephalopathy, Anoxia-Ischemia, Cerebral
Interventions: Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiogenic Shock
Interventions: Interscalene Block, PECS II Block, Superficial Cervical Plexus Block; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus, Coronary Artery Disease
Interventions: Aspirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Myocardial Infarction
Interventions: Prasugrel, Vorapaxar, Aspirin, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

SPIROCOR Coronary Outcome by Respiratory Stress Examination

Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

FAME II-10-year Follow-Up

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Study of Osteopathic Manipulation in the Management of Angina

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Identification of Brain Injury Using Portable MRI

Bright Light Exposure in Surgical Patients

MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms

Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Aspirin Dosing in Diabetic Patients

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor